ArticleFrontiers in immunology2026
Complement C1q promotes primary haemostasis in a microfluidic bleeding model.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In systemic inflammatory diseases, thrombotic complications often cannot be fully explained by traditional risk factors, suggesting that the immune system directly affects hemostasis. The complement system, particularly C1q (the recognition molecule of the classical complement pathway), has been shown to enhance primary hemostasis Aim: To investigate the role of the C1q-vWF interaction in human primary hemostasis. Methods: We used a microfluidic bleeding model with endothelialized microchannels to visualize hemostatic processes in real-time. Following mechanical vessel injury, we tracked C1q deposition and its colocalization with vWF, platelets, and fibrinogen using confocal microscopy. The functional relevance of C1q was assessed using the C1q-inhibitory peptide 2J. Results: C1q accumulates immediately at the injury site and exhibits strong colocalization with vWF and activated platelets, while colocalization with fibrinogen is minimal. Inhibiting C1q with peptide 2J significantly reduces both C1q and vWF deposition during early clot formation, and leads to prolonged bleeding time in this model. Conclusion: Deposited C1q functions as a binding partner for vWF, enhancing primary hemostasis. This C1q-vWF axis may contribute to inflammation-related thromboembolic complications in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.